公开(公告)号：US20060281805A1

公开(公告)日：2006-12-14

申请号：US10552456

申请日：2003-04-09

申请人： Anita Mehta ,  Bruhaspathy Miriyala ,  Sudershan Arora ,  Jang Gupta

发明人： Anita Mehta ,  Bruhaspathy Miriyala ,  Sudershan Arora ,  Jang Gupta

IPC分类号： A61K31/403 ,  C07D209/02

CPC分类号： C07D209/52

摘要： This invention relates to the derivatives of substituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods of treating the diseases mediated through muscarinic receptors.

公开(公告)号：US20060217432A1

公开(公告)日：2006-09-28

申请号：US10537851

申请日：2002-12-10

申请人： Anita Mehta ,  Arundutt Silamkoti ,  Bruhaspathy Miriyala ,  Sudershan Arora ,  Boju Srinivasulu ,  Bireshwar Mukherjee ,  Jang Gupta

发明人： Anita Mehta ,  Arundutt Silamkoti ,  Bruhaspathy Miriyala ,  Sudershan Arora ,  Boju Srinivasulu ,  Bireshwar Mukherjee ,  Jang Gupta

IPC分类号： A61K31/403 ,  C07D209/02

CPC分类号： C07D401/06 ,  C07D209/52 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14

摘要： The invention relates to derivatives of 3,6-disubstituted azabicyclo[3.1.0]hexanes of structure (I). The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

摘要翻译： 本发明涉及结构（I）的3,6-二取代的氮杂双环[3.1.0]己烷的衍生物。 本发明化合物可用作毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸道，尿路和胃肠道系统的各种疾病。 本发明还涉及含有本发明化合物的药物组合物和通过毒蕈碱受体介导的疾病的治疗方法。

公开(公告)号：US20050256128A1

公开(公告)日：2005-11-17

申请号：US10844992

申请日：2004-05-12

申请人： Sudershan Arora ,  Neelima Sinha ,  Rakesh Sinha ,  Ram Upadhyaya

发明人： Sudershan Arora ,  Neelima Sinha ,  Rakesh Sinha ,  Ram Upadhyaya

IPC分类号： A61K31/131 ,  A61K31/4409 ,  A61K31/496 ,  A61K31/4965 ,  A61K45/06 ,  A61K31/455

CPC分类号： A61K31/131 ,  A61K31/4409 ,  A61K31/496 ,  A61K31/4965 ,  A61K45/06 ,  A61K2300/00

摘要： An antimycobacterial combination and composition for treating tuberculosis are described. The compounds used are N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide of formula (I) or a pharmaceutically acceptable non-toxic salt thereof and an amount of one or more first line antitubercular drugs.

摘要翻译： 描述了用于治疗结核病的抗分支杆菌组合物和组合物。 使用的化合物是式（I）的N-（3 - [[4-（3-三氟甲基苯基）哌嗪基]甲基] -2-甲基-5-苯基 - 吡咯基）-4-吡啶基甲酰胺或药学上可接受的无毒盐 和一种或多种一线抗结核药物。

公开(公告)号：US20050249831A1

公开(公告)日：2005-11-10

申请号：US10525992

申请日：2003-08-27

申请人： Sudershan Arora ,  Vandita Srivastava ,  Veeranjaneyulu Addepalli ,  Sridhar Natesan ,  Rajan Goel

发明人： Sudershan Arora ,  Vandita Srivastava ,  Veeranjaneyulu Addepalli ,  Sridhar Natesan ,  Rajan Goel

IPC分类号： A61K20060101 ,  A61K31/704 ,  A61K35/00 ,  A61K36/77 ,  A61P20060101 ,  A61P25/06 ,  A61K35/78

CPC分类号： A61K36/77

摘要： A pharmaceutical composition comprising a herbal extract, comprising a mixture of saponins prepared from the pericarp of Sapindus trifoliatus, with binding affinities for the receptor sites viz. GABA-A agonist site, Glutamate-AMPA site, Glutamate-Kainate site, Glutamate-NMDA agonistic site, Glutamate-NMDA glycine (strychnine insensitive) site and Sodium channel (site 2), having major mediatory role in anticonvulsant activity. A process for preparation of the herbal extract; isolation of six pure compounds from the mixture of saponins in the aqueous extract; and a pharmaceutical composition comprising the said extract in combination with pharmaceutically acceptable additives. A method of prophylactic treatment of migraine through anticonvulsant activity of the composition by its administration through intranasal route.

摘要翻译： 包含草药提取物的药物组合物，其包含由Sapindus trifoliatus的果皮制备的皂苷的混合物，对受体位点的结合亲和力。 GABA-A激动剂位点，谷氨酸 - AMPA位点，谷氨酸 - 红藻酸酯位点，谷氨酸-N NMDA激动位点，谷氨酸-N NMDA甘氨酸（士的宁不敏感）位点和钠通道（位点2），在抗惊厥活性中具有主要的介导作用。 制备草药提取物的方法 在水提取物中从皂甙混合物中分离出六种纯化合物; 以及包含所述提取物与药学上可接受的添加剂组合的药物组合物。 一种通过鼻内途径施用组合物的抗惊厥活性来预防性治疗偏头痛的方法。

公开(公告)号：US20050192275A1

公开(公告)日：2005-09-01

申请号：US11082947

申请日：2005-03-18

申请人： Sudershan Arora ,  Vijaykumar Patil ,  Prathap Nair ,  Prasad Dixit ,  Shankar Ajay ,  Rakesh Sinha

发明人： Sudershan Arora ,  Vijaykumar Patil ,  Prathap Nair ,  Prasad Dixit ,  Shankar Ajay ,  Rakesh Sinha

IPC分类号： A61P31/00 ,  C07D263/20 ,  C07D413/10 ,  C07D413/14 ,  A61K31/541 ,  A61K31/422 ,  A61K31/496 ,  A61K31/5377 ,  C07D413/02 ,  C07D417/02

CPC分类号： C07D263/20 ,  C07D413/10 ,  C07D413/14

摘要： Novel compounds belonging to the class of oxazolidinones possessing potent antimycobacterial properties especially useful in the treatment of acid fast organisms such as Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai. The compound and its pharmaceutically acceptable salts thereof act as antibacterial agents. Also disclosed is a method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial conditions such as Mycobacterium tuberculosis, drug resistant Mycobacterium tuberculosis, Mycobacterium avium-intracellular complex, M. fortuitum and M. kansai, comprising administering an antimycobacterially effective amount of the said compound and/or pharmaceutically acceptable salts thereof. There is also disclosed a process for the manufacture of the said compound or its pharmaceutically acceptable salts.

摘要翻译： 属于恶唑烷酮类的新型化合物具有强效的抗分支杆菌特性，特别适用于治疗结核分枝杆菌，鸟分枝杆菌 - 细胞内复合物，偶然遗传和关西等酸性快速生物。 该化合物及其药学上可接受的盐作为抗菌剂。 还公开了一种抑制分枝杆菌细胞生长的方法以及治疗结核分枝杆菌，耐药性结核分枝杆菌，鸟分枝杆菌 - 细胞内复合物，偶发性偶联菌和关西氏菌等分枝杆菌病症的方法，其包括施用抗分枝杆菌有效量 的所述化合物和/或其药学上可接受的盐。 还公开了制备所述化合物或其药学上可接受的盐的方法。

公开(公告)号：US08338450B2

公开(公告)日：2012-12-25

申请号：US12679443

申请日：2008-09-19

申请人： Sudershan Arora ,  Neelima Sinha ,  Prathap Nair ,  Sai Kumar Chakka ,  Anil Hajare ,  Azmi Reddy ,  Pravin Patil ,  Majid Sayyed ,  Rajender Kumar Kamboj ,  K. H. Sreedhara Swamy ,  Rajan Goel

发明人： Sudershan Arora ,  Neelima Sinha ,  Prathap Nair ,  Sai Kumar Chakka ,  Anil Hajare ,  Azmi Reddy ,  Pravin Patil ,  Majid Sayyed ,  Rajender Kumar Kamboj ,  K. H. Sreedhara Swamy ,  Rajan Goel

IPC分类号： A61K31/44 ,  C07D221/02

CPC分类号： C07D451/02 ,  C07D451/14

摘要： The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved.

摘要翻译： 本发明涉及通式A的新化合物，其互变异构形式，其立体异构体，其药学上可接受的盐，含有它们的药物组合物，制备上述化合物的方法及其作为二肽基肽酶-IV（DPP- IV）抑制剂，其可用于治疗或预防特别是II型糖尿病的疾病，涉及糖尿病的其它并发症以及涉及DPP IV酶的其它病原性病症。

公开(公告)号：US20100291020A1

公开(公告)日：2010-11-18

申请号：US12679443

申请日：2008-09-19

申请人： Sudershan Arora ,  Neelima Sinha ,  Prathap Nair ,  Sai Kumar Chakka ,  Anil Hajare ,  Azmi Reddy ,  Pravin Patil ,  Majid Sayyed ,  Rajender Kumar Kamboj ,  K.H. Sreedhara Swamy ,  Rajan Goel

发明人： Sudershan Arora ,  Neelima Sinha ,  Prathap Nair ,  Sai Kumar Chakka ,  Anil Hajare ,  Azmi Reddy ,  Pravin Patil ,  Majid Sayyed ,  Rajender Kumar Kamboj ,  K.H. Sreedhara Swamy ,  Rajan Goel

IPC分类号： A61K31/785 ,  A61K31/397 ,  A61K31/439 ,  C07D221/22 ,  A61P3/10 ,  A61P3/08 ,  A61P9/10 ,  A61P3/04 ,  A61P3/06 ,  A61P3/00 ,  A61P9/12 ,  A61P19/10 ,  A61P35/00 ,  A61P9/00 ,  A61P29/00

CPC分类号： C07D451/02 ,  C07D451/14

摘要： The present invention is related to novel compounds of the general formula A, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or prevention of diseases particularly Type II diabetes, other complications related to diabetes and other pathogenic conditions in which DPP IV enzyme is involved.

摘要翻译： 本发明涉及通式A的新化合物，其互变异构形式，其立体异构体，其药学上可接受的盐，含有它们的药物组合物，制备上述化合物的方法及其作为二肽基肽酶-IV（DPP- IV）抑制剂，其可用于治疗或预防特别是II型糖尿病的疾病，涉及糖尿病的其它并发症以及涉及DPP IV酶的其它病原性病症。

公开(公告)号：US20080114031A1

公开(公告)日：2008-05-15

申请号：US11692362

申请日：2007-03-28

申请人： Viswajanani Sattigeri ,  Sudershan Arora ,  Mohammad Salman ,  Venkata Palle ,  Ashis Mukherji ,  Ashwani Verna ,  Sanjay Malhotra ,  Sankaranarayanan Dharmarajan ,  Abhijit Ray ,  Raj Shirumalla

发明人： Viswajanani Sattigeri ,  Sudershan Arora ,  Mohammad Salman ,  Venkata Palle ,  Ashis Mukherji ,  Ashwani Verna ,  Sanjay Malhotra ,  Sankaranarayanan Dharmarajan ,  Abhijit Ray ,  Raj Shirumalla

IPC分类号： A61K31/4525 ,  A61K31/34 ,  A61P17/00 ,  A61P29/00 ,  A61P3/10 ,  A61P35/00 ,  A61P37/00 ,  A61P9/00 ,  C07D307/20 ,  C07D405/02 ,  C07D405/14 ,  C07D413/02

CPC分类号： C07H9/04 ,  C07H3/02 ,  C07H15/00

摘要： The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis and allergic rhinitis. Pharmacological compositions containing compounds disclosed herein and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, Ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.

摘要翻译： 本发明涉及作为抗炎剂的单糖衍生物。 本文中的化合物障碍可用于抑制和预防炎症和相关病理，包括炎症和自身免疫性疾病，例如支气管哮喘，类风湿性关节炎，I型糖尿病，多发性硬化，同种异体移植排斥，牛皮癣，炎性肠病，溃疡性结肠炎，痤疮， 动脉粥样硬化，癌症，瘙痒和过敏性鼻炎。 包含本文公开的化合物的药理学组合物和治疗支气管哮喘，慢性阻塞性肺病，类风湿性关节炎，多发性硬化，I型糖尿病，牛皮癣，同种异体移植物排斥反应，炎症性肠病，溃疡性结肠炎，痤疮，动脉粥样硬化，癌症，瘙痒，过敏性 还提供使用该化合物的鼻炎和其它炎性和/或自身免疫性疾病。

公开(公告)号：US20060045930A1

公开(公告)日：2006-03-02

申请号：US10931814

申请日：2004-09-01

申请人： Sudershan Arora ,  Vandita Srivastava ,  Sameer Walunj

发明人： Sudershan Arora ,  Vandita Srivastava ,  Sameer Walunj

IPC分类号： A61K36/88 ,  A61K38/16

CPC分类号： A61K36/66 ,  Y02A50/39

摘要： A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-γ inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

公开(公告)号：US20050107370A1

公开(公告)日：2005-05-19

申请号：US10497615

申请日：2002-09-20

申请人： Sudershan Arora ,  Neelima Sinha ,  Sanjay Jain ,  Ram Upadhayaya ,  Gourhari Jana ,  Shankar Ajay ,  Rakesh Sinha

发明人： Sudershan Arora ,  Neelima Sinha ,  Sanjay Jain ,  Ram Upadhayaya ,  Gourhari Jana ,  Shankar Ajay ,  Rakesh Sinha

IPC分类号： A61P31/06 ,  C07D207/32 ,  C07D207/335 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D417/06 ,  C07D417/02 ,  A61K31/4025 ,  A61K31/426 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  C07D413/02 ,  C07D43/02

CPC分类号： C07D207/335 ,  C07D207/32 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D417/06

摘要： Novel pyrrole derivatives of formula (I) and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser toxicity compared to known compounds. The use of the novel compounds of formula (I) for treatment of latent tuberculosis including Multi Drug Resistant Tuberculosis (MDR TB). The methods for preparation of the novel compounds, pharmaceutical compositions containing the novel compounds and method of treating MDR TB by administration of compounds of formula (I).

摘要翻译： 式（I）的新型吡咯衍生物及其药学上可接受的酸加成盐对临床敏感性以及抗结核分枝杆菌菌株具有优异的抗分枝杆菌活性，并且与已知化合物相比具有较小的毒性。 使用式（I）的新化合物用于治疗潜在结核病，包括多药耐药性结核病（MDR TB）。 制备新化合物的方法，含有新化合物的药物组合物和通过施用式（I）化合物治疗MDR TB的方法。